14,234 Becton, Dickinson and Company $BDX Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. decreased its stake in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 5.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 256,265 shares of the medical instruments supplier’s stock after selling 14,234 shares during the quarter. Russell Investments Group Ltd. owned about 0.09% of Becton, Dickinson and Company worth $45,881,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of BDX. Moneco Advisors LLC grew its holdings in shares of Becton, Dickinson and Company by 2.6% during the third quarter. Moneco Advisors LLC now owns 2,071 shares of the medical instruments supplier’s stock valued at $371,000 after buying an additional 52 shares during the last quarter. Brown Lisle Cummings Inc. increased its position in shares of Becton, Dickinson and Company by 9.2% in the 2nd quarter. Brown Lisle Cummings Inc. now owns 644 shares of the medical instruments supplier’s stock valued at $97,000 after acquiring an additional 54 shares during the period. Pension & Wealth Management Advisors Inc. increased its position in shares of Becton, Dickinson and Company by 12.3% in the 3rd quarter. Pension & Wealth Management Advisors Inc. now owns 510 shares of the medical instruments supplier’s stock valued at $94,000 after acquiring an additional 56 shares during the period. Brighton Jones LLC raised its stake in Becton, Dickinson and Company by 0.7% in the 3rd quarter. Brighton Jones LLC now owns 8,942 shares of the medical instruments supplier’s stock worth $1,601,000 after acquiring an additional 58 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC raised its stake in Becton, Dickinson and Company by 3.7% in the 2nd quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock worth $256,000 after acquiring an additional 60 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $217.95 on Monday. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.87 and a quick ratio of 0.54. The stock has a market capitalization of $60.05 billion, a price-to-earnings ratio of 52.64, a PEG ratio of 3.65 and a beta of 0.22. The firm’s 50 day simple moving average is $190.90 and its 200-day simple moving average is $170.56. Becton, Dickinson and Company has a 12 month low of $140.11 and a 12 month high of $219.78.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.07 by $0.08. Becton, Dickinson and Company had a net margin of 5.66% and a return on equity of 14.90%. The firm had revenue of $5.27 billion during the quarter, compared to analysts’ expectations of $5.11 billion. During the same period in the previous year, the business posted $3.96 EPS. The business’s revenue was up 5.4% compared to the same quarter last year. Analysts expect that Becton, Dickinson and Company will post 13.21 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 31st. Shareholders of record on Thursday, December 10th will be issued a $1.06 dividend. The ex-dividend date of this dividend is Thursday, December 10th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. This represents a $4.24 dividend on an annualized basis and a yield of 1.9%. Becton, Dickinson and Company’s dividend payout ratio is presently 101.45%.

Becton, Dickinson and Company announced that its Board of Directors has approved a stock repurchase program on Thursday, November 5th that authorizes the company to repurchase 10,000,000 outstanding shares. This repurchase authorization authorizes the medical instruments supplier to reacquire up to 3.6% of its stock through open market purchases. Share repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Weiss Ratings raised Becton, Dickinson and Company from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, November 4th. JPMorgan Chase & Co. increased their price objective on Becton, Dickinson and Company from $170.00 to $202.00 and gave the company a “neutral” rating in a report on Friday, November 6th. Stifel Nicolaus set a $195.00 price objective on Becton, Dickinson and Company in a research note on Friday, August 7th. Bank of America lifted their target price on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Monday, August 31st. Finally, Wells Fargo & Company lifted their target price on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $197.47.

View Our Latest Research Report on BDX

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael Feld sold 165 shares of the company’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the completion of the transaction, the executive vice president directly owned 19,720 shares of the company’s stock, valued at $3,717,022.80. This represents a 0.83% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,993 shares of the stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $210.00, for a total value of $628,530.00. Following the transaction, the chief executive officer owned 110,163 shares in the company, valued at $23,134,230. This trade represents a 2.65% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 3,310 shares of company stock valued at $688,650. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.

Featured Articles

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.